risperidone / Generic mfg. - LARVOL DELTA

Recurrent hypothermia associated with atypical antipsychotics: a diagnostic challenge in a medically complex patient. (PubMed, Arch Clin Cases) - "We report the case of a 55-year-old woman with tuberous sclerosis, epilepsy, intellectual disability, and chronic kidney disease who developed recurrent episodes of hypothermia in temporal association with risperidone and subsequently olanzapine, with several episodes also accompanied by bradycardia, hypotension, and AKI...Recurrent episodes with a consistent clinical pattern resolved following substitution of atypical antipsychotics with haloperidol, supporting a probable drug-induced etiology...This report highlights the importance of recognizing this rare adverse effect and ensuring careful monitoring and timely adjustment of psychotropic treatment. The temporal association with AKI also raises the possibility of a bidirectional interaction, although the underlying mechanisms remain incompletely understood."

Journal • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Developmental Disorders • Endocrine Disorders • Epilepsy • Hypoglycemia • Hypotension • Infectious Disease • Mental Retardation • Nephrology • Renal Disease

QSAR-Guided Virtual Screening and Molecular Dynamics Reveal Olaparib as a Repurposing Lead Against α-Synuclein Aggregation. (PubMed, Int J Mol Sci) - "The top docking candidates were Olaparib (-7.91 kcal/mol), Paliperidone (-7.75 kcal/mol), Niraparib (-7.18 kcal/mol), Dordaviprone (-7.06 kcal/mol), and Parecoxib (-6.89 kcal/mol). These findings identify Olaparib as a novel high-affinity repurposing lead, while Paliperidone and Risperidone are reported as chemically informative secondary NAC-groove binders rather than proposed antiparkinsonian therapeutics, given that their dopamine D2-antagonist pharmacology is clinically associated with drug-induced parkinsonism. All of the candidates warrant experimental validation via thioflavin-T fluorescence or nuclear magnetic resonance (NMR) spectroscopy."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

A Long-Term, Open-Label, Study on Schizophrenia (clinicaltrials.gov) - P2/3 | N=560 | Terminated | Sponsor: Denovo Biopharma LLC | N=1210 ➔ 560

Enrollment change • CNS Disorders • Psychiatry • Schizophrenia

Employment trajectories following the diagnosis and after long-acting injectable antipsychotic treatment in patients with schizophrenia: A nationwide study. (PubMed, Aust N Z J Psychiatry) - "Employment outcomes in schizophrenia appear shaped by diagnostic and treatment-related transitions rather than static disease status. Stabilization after long-acting injectable initiation may be linked to incremental improvements in employment trajectories for some subgroups, but optimizing long-term vocational outcomes likely requires integrated psychosocial and vocational support."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Complex auditory hallucinations associated with hearing impairment in elderly adults. (PubMed, Ind Psychiatry J) - "All patients were treated with risperidone, melatonin, and hearing aids, leading to significant improvements in the frequency and intensity of hallucinations. This case series highlights the diverse nature of auditory hallucinations in elderly individuals with hearing impairment, stressing the importance of recognizing sensory deprivation as a contributing factor and utilizing a comprehensive approach to treatment."

Journal • CNS Disorders • Infectious Disease • Otorhinolaryngology • Psychiatry

tDCS&ASD: Result of tDCS in ASD Children With Comorbidities Like PANDAS, Rare Genetic Diseases or Autoimmune Disorders (clinicaltrials.gov) - P1/2 | N=180 | Completed | Sponsor: Spanish Foundation for Neurometrics Development | Enrolling by invitation ➔ Completed | Phase classification: P1 ➔ P1/2 | Trial completion date: Jun 2026 ➔ Sep 2026 | Trial primary completion date: Dec 2025 ➔ Aug 2026

Phase classification • Trial completion • Trial completion date • Trial primary completion date • Autism Spectrum Disorder • Genetic Disorders • Immunology • Rare Diseases

Diagnosis of Antipsychotic Medication-Induced Severe Hypertriglyceridaemia by the Phenomenon of Pseudohyponatraemia and Successful Management With Variable-Rate Intravenous Insulin Infusion: A Case Report. (PubMed, Case Rep Endocrinol) - "Acute pancreatitis did not develop during the inpatient admission or during outpatient follow-up, and triglyceride levels have fallen substantially (3.2 mmol/L at 5 months) having been switched from quetiapine and risperidone to aripiprazole, an SGA associated with less metabolic disturbance. This case demonstrates the safe and effective management of SGA-associated severe HTG with intravenous insulin infusion to prevent acute pancreatitis. It also highlights the utility of pseudohyponatraemia as a useful way of detecting severe HTG and the impact of SGA medications in the aetiology of severe HTG."

Journal • CNS Disorders • Diabetes • Dyslipidemia • Mental Retardation • Metabolic Disorders • Pancreatitis • Psychiatry • Severe Hypertriglyceridemia

Clinical Consequences of Inadvertent Intramuscular Administration of Subcutaneous Risperidone Formulation. (PubMed, Case Rep Psychiatry) - "She complained of mild pain at the injection site, but no other adverse consequences were noted. When a SC formulation is administered IM, it results in mild muscle pain, and unpredictable release of risperidone, but no other notable clinical problems."

Journal • Bipolar Disorder • CNS Disorders • Mood Disorders • Musculoskeletal Pain • Pain • Psychiatry

Antipsychotic-associated obsessive-compulsive symptoms and disorder: scoping review of mechanisms, comparative epidemiology and clinical implications. (PubMed, BJPsych Open) - "Evidence for inducing obsessive-compulsive symptoms varies across antipsychotics, being most consistent for clozapine and least for predominantly dopamine-blocking agents. Brief routine screening and a pragmatic response pathway may be considered in clozapine services, with vigilance for other agents as evidence accrues."

Journal • Review • CNS Disorders • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry

Laryngospasm and Generalized Dystonia After Risperidone ER in the Setting of Fluphenazine Therapy. (PubMed, J Clin Psychopharmacol) - No abstract available

Journal • CNS Disorders • Dystonia • Movement Disorders

Drug utilisation and adverse drug reaction monitoring in schizophrenic patients: A tertiary care hospital study in India. (PubMed, Bioinformation) - "Significant dose variations were noted in commonly used antipsychotics such as risperidone, olanzapine and aripiprazole, as well as benzodiazepines like clonazepam and lorazepam (p<0.001). Atypical antipsychotics predominated due to better tolerability and lower extrapyramidal side effects, highlighting evolving prescribing trends. Thus, structured evidence on drug utilization patterns and variability in dosing, help in optimizing rational prescribing practices in schizophrenia management."

Adverse drug reaction • Journal • CNS Disorders • Psychiatry • Schizophrenia

Risperidone-Induced Nasal Congestion and Increased Urinary Frequency. (PubMed, Cureus) - "Risperidone was subsequently discontinued and replaced with aripiprazole. This case suggests a probable association between risperidone and the development of nasal congestion and urinary frequency. Awareness of these uncommon adverse effects may help clinicians identify medication-related symptoms, avoid unnecessary investigations, and improve treatment adherence."

Journal • CNS Disorders • Otorhinolaryngology • Psychiatry

Interim data from ENIGMA – TRS 1 study of evenamide as add on therapy to antipsychotic Standard of Care in patients with treatment resistant schizophrenia (TRS). Difficulties in performing TRS study with TRRIP criteria: the CRO experience (WFSBP 2026) - "One aspect of the ENIGMA – TRS 1 study assesses plasma concentrations of standard of care as selected antipsychotics: Aripiprazole, Brexpiprazole, Cariprazine, Clozapine, Lurasidone, Olanzapine, Paliperidone, Quetiapine, Risperidone and Ziprasidone for subjects treated with those antipsychotics with daily therapeutic doses meeting local product labels requirements and correlated those with minimal duration of 6 weeks treatment with any of those medications. As the study is performed in 20 countries worldwide major issues reside in getting approval by all regulatory approvals, languages use for the rating instruments as well as for the training of the raters. Based on hundreds of patients entering screening, a large proportion failed the screening phase because of lack of adequate concentration of the primary AP. Difficulties have been noticed in ensuring adequate documentation of previous AP failures."

Clinical • CNS Disorders • Psychiatry • Schizophrenia

Haplotype-based association of HTR2A rs6311-rs6313 with early risperidone-clozapine response in Batak patients with schizophrenia. (PubMed, Pharmacogenet Genomics) - "HTR2A variation was associated with early risperidone-clozapine response, with consistent signals under the recessive model and at the haplotype level. Haplotype associations remained significant after permutation correction, suggesting that haplotype analysis may provide a more robust approach for detecting pharmacogenetic contributions to treatment response."

Journal • CNS Disorders • Gene Therapies • Psychiatry • Schizophrenia • HTR2A

Less Invasive Rapid Tranquilization in LMIC Emergency Settings: Comparison of Oral Risperidone Plus Clonazepam Versus Intramuscular Haloperidol in a Randomized Trial. (PubMed, Int J Soc Psychiatry) - "Therefore, the two regimens should not be considered fully interchangeable in all emergency presentations. We found that oral techniques may enable more humane, less invasive, and culturally acceptable emergency care in LMICs due to the social burden of injectable medication, which typically requires restraint."

Journal • CNS Disorders • Psychiatry • Psychomotor Agitation

More Than Recurrent Cholangitis: Drug-Induced Cholestatic Liver Injury in a Patient With History of Kasai Portoenterostomy (ACG 2026) - "Given his history of recurrent cholangitis and cholestatic liver injury, gastroenterology recommended empiric Zosyn for presumed cholangitis...Risperidone was discontinued with subsequent improvement in jaundice and liver function tests...Figure: Figure 2. Magnetic resonance cholangiopancreatography (MRCP) demonstrating dilation of the biliary tree, most specifically intrahepatic ductal dilation."

Clinical • Bipolar Disorder • CNS Disorders • Fibrosis • Hepatology • Immunology • Liver Failure • Pruritus

Identification of novel peripherally restricted risperidone-like dopamine D2 receptor antagonists for prolactin-mediated neuroprotection through a multi-stage in silico screening. (PubMed, PLoS One) - "These findings suggest that the identified compounds may serve as computationally prioritized candidates for the development of peripherally restricted D2R antagonists. However, their functional D2R antagonism, actual BBB exclusion, prolactin-elevating activity, and ability to reproduce CNS neuroprotection without direct central D2R modulation remain to be experimentally validated."

Journal • Alzheimer's Disease • Anesthesia • Cognitive Disorders • DRD2

Detected Delirium Prevalence and Practices in Australia and New Zealand: A Sub-Analysis of the World Delirium Awareness Day Prevalence Study. (PubMed, Australas J Ageing) - "In Australia and New Zealand, delirium assessment practices have improved over time. Non-pharmacological strategies are widely used; however, antipsychotic use remains substantial. Workforce constraints, education gaps and system pressures may contribute to variability in delirium care delivery. Addressing these factors, alongside engagement with carers, may support further improvements in care. Ongoing surveillance through repeated surveys would help monitor trends in delirium care over time."

Journal • CNS Disorders • Pain

POPS or POP02: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (clinicaltrials.gov) - P=N/A | N=5000 | Recruiting | Sponsor: Duke University | Trial completion date: Jul 2027 ➔ Dec 2026 | Trial primary completion date: Mar 2027 ➔ Nov 2026

Trial completion date • Trial primary completion date • ADHD (Impulsive Aggression) • Asthma • Attention Deficit Hyperactivity Disorder • Bronchopulmonary Dysplasia • Cardiovascular • CNS Disorders • Dermatology • Developmental Disorders • Endocrine Disorders • Genetic Disorders • Gynecology • Heart Failure • Hematological Disorders • Hemophilia • Hypertension • Immunology • Infectious Disease • Insomnia • Metabolic Disorders • Nephrology • Novel Coronavirus Disease • Pain • Pneumonia • Psychiatry • Pulmonary Arterial Hypertension • Pulmonary Disease • Rare Diseases • Renal Disease • Respiratory Diseases • Sleep Disorder

Neuropsychiatric pleiotropy in 7q11.23 microduplication: A Case Report (WFSBP 2026) - "This case supports dup7q11.23 as a rare-variant risk state for a clinically significant ASD– chronic motor tic–OCD phenotype into young adulthood and highlights aripiprazole as a potentially useful option when standard tic-targeting agents are inadequate, warranting systematic study in genetically defined subgroups."

Case report • Clinical • CNS Disorders • Mood Disorders • Movement Disorders • Obsessive-Compulsive Disorder • Psychiatry • Tic Disorders • Tourette Syndrome

Isolated Delusion of Time in Post-Traumatic Psychosis (WFSBP 2026) - "Treatment with risperidone led to gradual resolution of symptoms and functional recovery over 6 months... Temporal disorientation does not necessarily indicate delirium or dementia. Selective disturbances of temporal belief can emerge from focal frontotemporal injury. Such presentations broaden the phenomenology of post-traumatic psychosis and emphasise modular cognitive networks underlying time perception."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Psychiatry • Vascular Neurology

Methylphenidate induced psychosis in adolescent with attention deficit hyperactivity disorder (WFSBP 2026) - "Following initiation of risperidone 2 mg/day and clonidine 0.05 mg/day, hallucinations improved significantly within four weeks. Methylphenidate-induced psychosis is a rare but important adverse effect in children and adolescents with ADHD. This case highlights the emergence of auditory hallucinations during long-term methylphenidate treatment and their subsequent improvement following pharmacological intervention. Clinicians should closely monitor for psychotic symptoms during stimulant therapy to ensure timely identification and appropriate management."

ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Results of Study 008A with evenamide add-on to second-generation antipsychotics in India: influence of cultural, religious, and common background factors on efficacy (WFSBP 2026) - "clozapine) conducted in 11 countries (Asia, Latin America, Europe)...A significant higher proportion of patients was taking risperidone in India... These results point out that the effect of evenamide on the PANSS Total score is statistically significant in India despite the study being performed in 9 languages, and the magnitude of effect observed in India does not differ compared to other countries (-3.0 vs -2.7). More details and considerations will be presented at the Congress."

Clinical • CNS Disorders • Schizophrenia

CYP450 Polymorphism Profile in Treatment-Resistant Schizophrenia (WFSBP 2026) - " A pharmacogenomic panel was applied to studied cohort that included CYP2D6 for aripiprazole; CYP1A1 for olanzapine; ABCB1 for clozapine; RGS4 for risperidone; and SLC22A1 for anticholinergic sensitivity. These findings demonstrates genetic variability among the studied cases with high frequency of variations that may cause likelihood of adverse drug reactions or toxicity, establishing pharmacogenomic screening as an evidence-based clinical necessity rather than an adjunctive tool in contemporary psychiatric practice."

CNS Disorders • Psychiatry • Schizophrenia • ABCB1 • CYP1A1 • RGS4 • SLC22A1

Chronic Sympathomimetic stimulation to Catecholaminergic Dysregulation: A neurobiological Case analysis of Mephentermine-Induced Mania (WFSBP 2026) - "After stopping mephentermine and starting valproate 1500 mg, risperidone 2 mg, and lorazepam 2 mg, marked improvement occurred within weeks. This case underscores the neurobiological impact of chronic sympathomimetic misuse in precipitating manic syndromes. Early identification of pharmacologically driven affective states and integrated mood stabilization with de-addiction strategies are crucial for favorable outcomes."

Clinical • Bipolar Disorder • CNS Disorders • Mood Disorders